Comparison of vitamin D3 and N-acetylcysteine prescription in COVID-19 patients and their effect on recovery process

Comparison of vitamin D3 and N-acetylcysteine prescription in COVID19 patients and their effect on recovery process

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200324046850N1

Enrollment

100

Registered

2020-03-29

Start date

2020-06-06

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19. Other coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention 1: Intervention group 1: Patients receiving standard country protocol drugs(lopinavir (50 mg) –ritonavir (200 mg) 2 tablets every 12 hours until the patient's clinical symptoms improve +

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: COVID-19 patients that have positive PCR test of nasopharyngeal sample or have positive CT Scan for COVID-19.

Exclusion criteria

Exclusion criteria: Pregnant or breast feeding women Patients under 18 years of age Any life-threatening factor

Design outcomes

Primary

Measure	Time frame
Time to clinical improvement defined as start of taking medication time to Discharge Time. Timepoint: The beginning of the study ,the seventh day, the fourteenth day, the twenty-first day, the twenty-eighth day. Method of measurement: Medical record.	—

Secondary

Measure	Time frame
Complete Blood Count. Timepoint: The beginning of the study and the time of discharge. Method of measurement: blood sample.;Venous blood gas. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;C-reactive-protein. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;Creatinne. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;Aspartate amino transferase. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;Alanine amino transferase. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;Prothrombin time. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;Partial Thromboplastin time. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;Cough. Timepoint: The beginning of the study ,the seventh day, the fourteenth day, the twenty-first day, the twenty-eighth day. Method of measurement: Clinical observation and examination.;Level of consciousness. Timepoint: The beginning of the study ,the seventh day, the fourteenth day, the twenty-first day, the twenty-eighth day. Method of measurement: Using the Glasgow Coma scale.;Shortness of breath. Timepoint: The beginning of the study, the seventh day, the fourteenth day, the twenty-first day, the twenty-eighth day. Method of measurement: Clinical observation and examination.;Fatigue. Timepoint: The beginning of the study, the seventh day, the fourteenth day, the twenty-first day, the twenty-eighth day. Method of measurement: Observation and Interview with the patient.;Severe and frequent diarrhea. Timepoint: The beginning of the study, the seventh day, the fourteenth day, the twenty-first day, the twenty-eighth day. Method of measurement: Interview with the patient.;Abdominal pain. Time	—

Measure

Time frame

Complete Blood Count. Timepoint: The beginning of the study and the time of discharge. Method of measurement: blood sample.;Venous blood gas. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;C-reactive-protein. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;Creatinne. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;Aspartate amino transferase. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;Alanine amino transferase. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;Prothrombin time. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;Partial Thromboplastin time. Timepoint: The beginning of the study and the time of discharge. Method of measurement: Blood sample.;Cough. Timepoint: The beginning of the study ,the seventh day, the fourteenth day, the twenty-first day, the twenty-eighth day. Method of measurement: Clinical observation and examination.;Level of consciousness. Timepoint: The beginning of the study ,the seventh day, the fourteenth day, the twenty-first day, the twenty-eighth day. Method of measurement: Using the Glasgow Coma scale.;Shortness of breath. Timepoint: The beginning of the study, the seventh day, the fourteenth day, the twenty-first day, the twenty-eighth day. Method of measurement: Clinical observation and examination.;Fatigue. Timepoint: The beginning of the study, the seventh day, the fourteenth day, the twenty-first day, the twenty-eighth day. Method of measurement: Observation and Interview with the patient.;Severe and frequent diarrhea. Timepoint: The beginning of the study, the seventh day, the fourteenth day, the twenty-first day, the twenty-eighth day. Method of measurement: Interview with the patient.;Abdominal pain. Time

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSara Mobarak

Abadan University of Medical Sciences

s.mobarak@abadanums.ac.ir+98 61 5338 4004

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026